The FDA approved external trigeminal nerve stimulation (TNS) in 2019 as the first non-drug device for treating ADHD, ...

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Millions of adults around the world are diagnosed with ADHD every year, and there is a great need for research in the field. However, much clinical research on adult ADHD suffers from serious ...

FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.

ADHD diagnosis, which largely originated in the United States, began to spread to the rest of the globe in the late 1990s, ...

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was marked by loud, restless boys who couldn’t sit quietly in class. Girls and women ...

Attention-deficit/hyperactivity disorder is one of the most researched neurodevelopmental conditions, yet 5 ADHD myths people ...

ADHD is associated with impulsivity, hyperactivity, and trouble with focus, but kids with ADHD may also struggle with motor ...

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

Despite decades of research, these ADHD myths still affect how people understand attention and behavior.